Australian company Starpharma reported a sharp lift in annual revenue and a narrower loss for the year to 30 June 2026, driven by an upfront payment from its Genentech licence agreement and followed by a $30 million capital raise that the company says extends its funding runway into 2028.
The Melbourne-based company recorded revenue of $12 million in 2026, up 145 per cent from $4.9 million a year earlier. The main contributor was an $8.3 million upfront payment under the Genentech licensing deal, alongside product sales, royalties and other licence and research income.
Starpharma’s reported loss narrowed by 25 per cent to $7.5 million, compared with $10 million in 2025, although investment in its development programs continued to rise. Research and product development expenditure increased to $11.1 million from $8.4 million, after taking account of the Australian Government’s research and development tax incentive.
The company ended the financial year with $11 million in cash. Since 30 June, it has raised net proceeds of $30 million through an entitlement offer, strengthening its balance sheet as it seeks to advance its oncology pipeline.
Central to that effort is DEP HER2-Lutetium, Starpharma’s lead radiopharmaceutical program. The company said it had made significant progress on the asset during 2026 while also developing other early-stage next-generation therapies based on its dendrimer-enhanced product technology.
Chief executive Cheryl Maley said the year had brought advances in the company’s lead radiopharmaceutical program, new strategic partnerships and further validation of the potential for DEP technology in targeted cancer treatment.
“Our focus remains on building long-term shareholder value through the development of a pipeline of targeted oncology therapies enabled by our DEP technology,” Maley said.
Starpharma develops dendrimers, precisely manufactured nanoscale molecules whose structure, branching and water solubility can be used in medical and pharmaceutical applications. Its portfolio spans clinical-stage DEP assets, preclinical radiopharmaceutical programs, research collaborations and three over-the-counter products already on the market.
